Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats prurigo nodularis. Sold as Nemluvio. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 2 applications for Nemolizumab-ilto (sold as Nemluvio), first approved Aug 12, 2024, with 0 new uses approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Nemluvio
$54.1M for 9,644 prescriptions, +7833% on 2024
How its trials ended
17 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Of the 7 whose ending is known, 86% met their primary endpoint, 0% missed it and 14% stopped early.
Completed, result not reported741%Completed, result not reportedCount7Share41%
Met its primary endpoint635%Met its primary endpointCount6Share35%
Ongoing318%OngoingCount3Share18%
Stopped: other or unclear16%Stopped: other or unclearCount1Share6%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
First approved in Japan 29 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Mitchga, new approvalA drug with a new indication and a new dosage for the treatment of prurigo nodularis in patients who have not responded sufficiently to conventional… · Maruho Co., Ltd. · Mar 26, 2024
Mitchga, new ingredientA drug with a new active ingredient indicated for the treatment of pruritus associated with atopic dermatitis (for use only in patients who have not… · Maruho Co., Ltd. · Mar 28, 2022 · Review report
Approvals in Canada (Health Canada)
First approved in Canada 16 months after the US. New drug submissions since 1994, matched by ingredient; see all Canadian approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA